Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

Patents 494show all

  • 198
    C12N - Microorganisms or enzymes
  • 100
    A61K - Preparations for medical, dental, or toilet purposes
  • 47
    C07H - Sugars
  • 41
    C07K - Peptides
  • 38
    C12Y - Enzymes
  • 26
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 21
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 8
    A01K - Animal husbandry
  • 5
    C07C - Acyclic or carbocyclic compounds
  • 5
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Clinical Trials 37show all

13Phase 213Phase 34N/A4Phase 12Phase 2/Phase 31Other

SEC Filings show all


2
D

1
S-1

Contact Information

6501 Dumbarton Circle.
Fremont, CA 94555
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$61,399,00051-1002010-06-01Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2008-04-18$13,900,000Series HTako Ventures, SBI Asset Management
2008-07-04$27,000,000Series UnknownSBI Asset Management
2006-01-01$10,499,000Series GTako Ventures
2010-06-01$10,000,000Series Unknown
2001-09-11Series F

SEC Form D Funding Events

DateOfferedSoldType
2010-06-01$10,000,000$10,000,000Equity, Option to Acquire, Security to be Acquired, Other
2008-04-08Unknown Unknown Other (Paper Filing)

Key Executives

  • Daniel Zurr, Ph.D.
    Executive Officer, Director
  • Rami Skaliter
    Executive Officer
  • Shai Erlich, Ph.D.
    Executive Officer
  • Elena Feinstein, Ph.D.
    Executive Officer
  • Juliana Friedmann, M.Sc.
    Executive Officer
  • Smadar Shakked
    Executive Officer
  • James D. Thompson, Ph.D.
    Executive Officer
  • Carlos Benaim, M.Sc.
    Executive Officer
  • Robert L. Jones
    Executive Officer
  • Philip B. Simon
    Director
  • Kazuyuki Matsui
    Director
  • Toru Mio
    Director
  • Trent M. Gunter
    Director
  • Philip M. Hahn
    Director
  • Peter A. Thompson, M.D.
    Director